Related Experiment Videos
Difference between renal failure associated with methylprednisolone pulse therapy and deterioration of renal function
T Sakemi1, S Fujimoto, S Fujimi
1Department of Internal Medicine, Saga Medical School, Japan.
Abstract:
In this study, we attempted to analyze the differences between renal failure associated with methylprednisolone (MP) pulse therapy and natural deterioration of renal function that was unrelated to MP administration. Of 80 patients with renal or collagen disease who received MP pulse therapy at our hospitals, 13 were selected for the study whose serum creatinine levels increased more than 0.5 mg/dl from baseline values following therapy. Somewhat arbitrarily, 7 patients were placed in an MP-associated renal deterioration group (group 1) in which serum creatinine levels returned naturally, or following induced diuresis, to baseline levels, and 6 patients in an MP-independent natural deterioration group (group 2) in which renal function progressively deteriorated. Renal function similarly deteriorated in the two groups following pulse therapy, irrespective of the degree of crescent formation. Our data suggested that hypoproteinemia is the most important index for differentiating MP-associated renal failure from natural deterioration of renal function unrelated to MP pulse therapy. In patients that are nephrotic and have impaired renal function, worsening of renal function following pulse therapy may partly be due to transient MP-associated renal failure. On the other hand, in patients without hypoproteinemia, worsening of renal function is most likely due to active primary disease and is probably not associated with MP pulse therapy.
Insights
Hypoproteinemia helps distinguish kidney damage from methylprednisolone (MP) pulse therapy versus natural disease progression in patients with renal or collagen diseases. Low protein levels indicate MP-related kidney issues, while normal levels suggest primary disease activity.
Area of Science:
- Nephrology
- Pharmacology
- Immunology
Background:
- Methylprednisolone (MP) pulse therapy is used for renal and collagen diseases.
- Acute kidney injury can occur during or after MP pulse therapy.
- Differentiating MP-induced renal failure from disease progression is clinically important.
Purpose of the Study:
- To analyze differences between MP-associated renal failure and natural renal function deterioration.
- To identify clinical indicators for differentiating these two conditions.
Main Methods:
- Retrospective analysis of 13 patients with renal or collagen disease receiving MP pulse therapy.
- Patients selected had serum creatinine increase >0.5 mg/dl post-therapy.
- Group 1: MP-associated deterioration (renal function recovery). Group 2: MP-independent deterioration (progressive decline).
Main Results:
- Renal function deteriorated similarly in both groups post-therapy, regardless of crescent formation.
- Hypoproteinemia was the most significant differentiator between MP-associated and independent renal failure.
- Nephrotic patients with impaired renal function may experience transient MP-related renal failure.
Conclusions:
- Hypoproteinemia is a key indicator for distinguishing MP-associated renal failure from natural deterioration.
- Worsening renal function in nephrotic patients post-MP therapy may be partly MP-induced.
- In non-nephrotic patients, worsening renal function likely reflects primary disease activity, not MP association.